在HR+/HER2-乳腺癌中减少内分泌治疗:尽管指导方针没有改变,但全国趋势仍在持续
Eline E F Verreck1, Emily L Postma2, Tanja Oostergo3
1Department of Surgery, Diakonessenhuis, Utrecht, the Netherlands; Department of Surgery, Erasmus Medical Centre, Rotterdam, the Netherlands.
Breast (Edinburgh, Scotland)
|December 3, 2025
概括
较少的激素受体阳性,HER2阴性乳腺癌患者正在接受内分泌疗法 (ET),尽管指南没有改变. 在荷兰观察到的这种趋势表明,更谨慎的医生方法可能会影响ET启动率.
科学领域:
- 在瘤学瘤学.
- 临床研究 临床研究
- 公共卫生 公共卫生
背景情况:
- 辅助系统治疗改善了乳腺癌的结果.
- 对于HR+/HER2-乳腺癌,化疗的使用正在减少.
- 对HR+/HER2-乳腺癌的内分泌治疗 (ET) 建议保持不变.
研究的目的:
- 为了检查荷兰HR+/HER2-乳腺癌患者ET启动的趋势.
- 通过时间来确定影响ET启动的因素.
- 评估ET使用的区域差异.
主要方法:
- 来自荷兰癌症登记处的127,610名HR+/HER2-患者的分析 (2012-2022年).
- 基于ET指南指示的分类 (病理,临床或没有).
- 使用PREDICT 2.0工具和因子分析后勤回归来估计ET益处.
主要成果:
- ET发起率从2012年的91.2%下降到2022年的79.3%.
- 较低的ET启动与较年轻 (30-39岁) 和较老 (>80岁) 的年龄组以及学术性医院治疗有关.
- 在2022年,ET启动的区域差异显著 (高达19个百分点).
结论:
- 尽管有稳定的指导方针,但HR+/HER2-乳腺癌的ET发病率有所下降.
- 医生隐可能有助于减少ET使用.
- 观察到的趋势和区域差异需要进一步调查治疗决策.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.5K
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
3.7K
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Receptor Downregulation in MVBs
2.7K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.7K
